"Losartan" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
| Descriptor ID |
D019808
|
| MeSH Number(s) |
D02.455.426.559.389.185.475 D03.383.129.308.507 D03.383.129.617.467
|
| Concept/Terms |
Losartan- Losartan
- 2-Butyl-4-chloro-1-((2'-(1H-etrazol-5-yl) (1,1'-biphenyl)-4-yl)methyl)-1H-imidazole-5-methanol
Losartan Potassium- Losartan Potassium
- Potassium, Losartan
- Losartan Monopotassium Salt
- Monopotassium Salt, Losartan
- Salt, Losartan Monopotassium
|
Below are MeSH descriptors whose meaning is more general than "Losartan".
Below are MeSH descriptors whose meaning is more specific than "Losartan".
This graph shows the total number of publications written about "Losartan" by people in this website by year, and whether "Losartan" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 0 | 2 | 2 |
| 2004 | 1 | 1 | 2 |
| 2006 | 1 | 1 | 2 |
| 2007 | 0 | 1 | 1 |
| 2011 | 1 | 0 | 1 |
| 2012 | 1 | 2 | 3 |
| 2013 | 0 | 1 | 1 |
| 2014 | 4 | 1 | 5 |
| 2015 | 1 | 2 | 3 |
| 2016 | 0 | 1 | 1 |
| 2018 | 2 | 2 | 4 |
| 2019 | 2 | 0 | 2 |
| 2020 | 3 | 0 | 3 |
| 2022 | 0 | 2 | 2 |
| 2024 | 1 | 0 | 1 |
| 2026 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Losartan" by people in Profiles.
-
Biologically Regulated Marrow Stimulation by Blocking TGF-?1 With Losartan Oral Administration Results in Hyaline-like Cartilage Repair: A Rabbit Osteochondral Defect Model. Am J Sports Med. 2020 03; 48(4):974-984.
-
Health-Related Quality of Life in Children and Young Adults with Marfan Syndrome. J Pediatr. 2019 01; 204:250-255.e1.
-
Predictors of Rapid Aortic Root Dilation and Referral for Aortic Surgery in Marfan Syndrome. Pediatr Cardiol. 2018 Oct; 39(7):1453-1461.
-
Influence of Aortic Stiffness on Aortic-Root Growth Rate and Outcome in Patients With the Marfan Syndrome. Am J Cardiol. 2018 05 01; 121(9):1094-1101.
-
Abnormal muscle mechanosignaling triggers cardiomyopathy in mice with Marfan syndrome. J Clin Invest. 2014 Mar; 124(3):1329-39.
-
Comparative effectiveness of individual angiotensin receptor blockers on risk of mortality in patients with chronic heart failure. Pharmacoepidemiol Drug Saf. 2012 Mar; 21(3):233-40.
-
Targeting TGF-beta and the extracellular matrix in Marfan's syndrome. Dev Cell. 2008 Jul; 15(1):1-2.
-
Angiotensin II stimulates spinally projecting paraventricular neurons through presynaptic disinhibition. J Neurosci. 2003 Jun 15; 23(12):5041-9.
-
Angiotensin II induces alpha3(IV) collagen expression in cultured murine proximal tubular cells. Proc Assoc Am Physicians. 1999 Jul-Aug; 111(4):357-64.
-
Topical application of AT1 receptor antagonists prevents medial and neointimal proliferation after balloon injury. Blood Press Suppl. 1994; 5:38-42.